

Continuous Glucose Monitoring (CGM) Systems for Diabetes Management

Continuous Glucose Monitoring (CGM) Systems for Diabetes Management

A second dossier has been received by the NYS Department of Health to review the current evidence for continuous glucose monitoring systems. A continuous glucose monitor (CGM) is a small wearable glucose monitoring device that continuously measures and tracks a person's glucose levels for the management of diabetes.

New York State Medicaid currently covers real-time continuous glucose monitoring for members with a diagnosis of type 1 diabetes.

The New York State Department of Health will make a determination whether to modify New York State Medicaid coverage of this technology.

Dossier sources of evidence already submitted:

The following evidence was recently submitted to the Department of Health:

1. AHRQ. AHRQ Systematic Review Surveillance Program: CER #57: Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness. 2016. <https://effectivehealthcare.ahrq.gov/ehc/products/242/2182/insulin-blood-sugar-surveillance-160215.pdf>
2. Alfadhli E, Osman E, Basri T. Use of a real time continuous glucose monitoring system as an educational tool for patients with gestational diabetes. *Diabetology & Metabolic Syndrome*. 2016;8:48.
3. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. *Diabetes Care*. 2011;34(4):795-800. doi:10.2337/dc10-1989.
4. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: A randomized controlled trial. *Diabetologia*. 2012;55(12):3155-3162.
5. Benkhadra K, Alahdab F, Tamhane S, et al. Real-time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta-analysis. *Clinical Endocrinology*. 2017 Mar;86(3):354-360.
6. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. *N Engl J Med*. 2010 Jul22;363(4):311-320.

7. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. *N Engl J Med*. 2013 Jul 18;369:224-232.
8. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. *Diabetes Care*. 2001 Nov;24(11):1858–1862.
9. Bronstone A, Graham C. The potential cost implications of averting severe hypoglycemic events requiring hospitalization in high-risk adults with type 1 diabetes using real-time continuous glucose monitoring. *J Diabetes Sci Technol*. 2016 Jun 28;10(4):905-913.
10. Bukara-Radujkovic G, Zdravkovic D, Lakic, S. Short-term use of continuous glucose monitoring system adds to glycemic control in young type 1 diabetes mellitus patients in the long run: a clinical trial. *Vojnosanit Pregl*. 2011 Aug;68(8):650-654.
11. Buckingham BA, Raghinaru, D, Cameron, F, et al. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. *Diabetes Care*. 2015 Jul;38(7):1197–1204.
12. Chetty VT, Almulla A, Oduyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in type I diabetic patients: A systematic review. *Diabetes Res Clin Pract*. 2008 Jul;81(1):79-87.
13. Cordua S, Secher AL, Ringholm L, Damm P, Mathiesen ER. Real-time continuous glucose monitoring during labour and delivery in women with Type 1 diabetes - observations from a randomized controlled trial. *Diabet Med*. 2013;30(11):1374-1381. doi:10.1111/dme.12246.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329(14):977-986.
15. The Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005;353(25):2643-2653.

16. Dinapoli TP. Diabetes in New York State. New York; 2015.
https://www.osc.state.ny.us/reports/health/diabetes_2015.pdf
17. ECRI Institute. Threshold suspend Insulin Delivery Systems for Managing Hypoglycemia in Patients with Type 1 Diabetes Mellitus. HTA Inf Serv. 2016;(July):1-48.
18. Floyd B, Chandra P, Hall S, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J Diabetes Sci Technol. 2012 Sep 1;6(5):1094-1102.
19. Fonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: a Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22(8):1008-1021. doi:10.4158/EP161392.CS.
20. Fonda SJ, Graham C, Munakata J, Powers JM, Price D, Vigersky RA. The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. J Diabetes Sci Technol. 2016 Jun 28;10(4):898-904. doi:10.1177/1932296816628547.
21. Gandhi GY, Kovalaske M, Kudva Y, et al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. J Diabetes Sci Technol. 2011 Jul 1;5(4):952-965.
22. Garg S, Brazg RL, Bailey TS, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012 Mar;14(3):205-209.
23. Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017 Mar;19(3):1-9. doi:10.1089/dia.2016.0421.
24. Golden SH, Brown T, Yeh HC, et al. Methods for insulin delivery and glucose monitoring: comparative effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Jul. (Comparative Effectiveness Reviews, No. 57.) Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK99217/>
25. Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm. 2012 Aug;18(6 Suppl):S1-S17.

26. Golicki DT, Golicka D, Groele L, Pankowska E. Continuous glucose monitoring system in children with type 1 diabetes mellitus: a systematic review and meta-analysis. *Diabetologia*. 2008 Feb;51(2):233-240.
27. Hermanides J, Nørgaard K, Bruttomesso D, et al. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type1 diabetes; a randomized controlled trial. *Diabet Med*. 2011 Oct;28(10):1158-1167.
28. Hirsch IB, Abelseh J, Bode BW, et al. Sensor-augmented insulin pump therapy: Results of the first randomized treat-to-target study. *Diabetes Technol Ther*. 2008 Oct;10(5):377-383.
29. Hoeks LB, Greven WL, de Valk HW. Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review. *Diabet Med*. 2011 Ap;28(4):386-394.
30. IQWiG. Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Mar. Executive Summary of Final Report No. D12-01. Available from: https://www.iqwig.de/download/D12-01_Executive-Summary_Continuous-glucose-monitoring-CGM-with-real-time-measurement-devices.pdf.
31. IQWiG. Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus (FINAL REPORT IN GERMANY). *Heal Technol Assess Database*. 2015;(3). Available from: https://www.iqwig.de/download/D12-01_Abschlussbericht_Kontinuierliche-Glukosemessung-mit-Real-Time-Messgeraeten.pdf
32. Kerr D, Fayers K. Continuous real-time glucose monitoring systems: time for a closer look. *Pr Diab Int*. 2008;25(1):37–41.
33. Kordonouri, O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: Results of the Paediatric Onset Study (ONSET) after 12 months of treatment. *Diabetologia*, 2010 Dec;53(12):2487-2495.
34. Langendam M, Luijck YM, Hooft L, DeVries JH, Mudde AH, ScholtenRJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. *Cochrane.Database.Syst.Rev*. 2012 Jan 18;1:CD008101.
35. Lo Scalzo A, Lenzi L, Chiarolla E, et al. HTA report: new devices for the management of glycaemia in young diabetics, Rome, September 2012.

36. Ly TT, Brnabic AJ, Eggleston A, et al. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. *Value Health*. 2014 Jul;17(5):561-569. doi:10.1016/j.jval.2014.05.008.
37. Matsuda E, Brennan P. The effectiveness of continuous glucose monitoring for type 1 diabetic adolescents using continuous subcutaneous insulin infusion pumps: A systematic review. *JBI Database of Systematic Reviews and Implementation Reports*. 2014;12(5):88-120.
38. Medical Advisory Secretariat. Continuous glucose monitoring for patients with diabetes: an evidence based analysis. *Ont Health Technol Assess Ser* [Internet]. 2011 July; 11(4):1-29.
39. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D exchange clinic registry. *Diabetes Care*. 2015 Jun;38(6):971-978. doi:10.2337/dc15-0078.
40. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. *BMJ*. 2008;337:907-910.
41. National Institute of Clinical Excellence. Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system). *NICE Clin Guid*. 2016 Feb. Available from: <https://www.nice.org.uk/guidance/dg21>
42. Newman SP, Cooke D, Casbard, A, et al. A randomized controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). *Health Technol Assess*. 2009 May;13(28):iii-xi,1-194.
43. O'Connell MA, Donath S, O'Neal DN, et al. Glycemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. *Diabetologia*. 2009 Jul;52(7):1250–1257.
44. Pickup JC, Freeman SC, Sutton AJ. Glycemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ*. 2011 Jul 7;343:d3805. doi: 10.1136/bmj.d3805.

45. Poolsup N, Suksomboon N, Kyaw AM. Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. *Diabetol Metab Syndr*. 2013;5:39.
46. Raccach D, Sulmont V, Reznik Y, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. *Diabetes Care*. 2009 Dec;32(12):2245-2250.
47. Riemsma R, Ramos IC, Birnie R, et al. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. *Health Technol Assess*. 2016 Feb;20(17).
48. Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. *Diabet Med*. 2015 May;32(5):618-626. doi:10.1111/dme.12661.
49. SBU Alert Report no 2013-04. Continuous subcutaneous glucose monitoring for diabetes. Available from: www.sbu.se/201304e
50. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The effect of real-time continuous glucose monitoring in pregnant women with diabetes A randomized controlled trial. *Diabetes Care*. 2013 Jul;36(7):1877-1883.
51. Solans M, Kotzeva A, Almazán A. Sistemas de monitorización continua de glucose en tiempo real. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Ministerio de Ciencia e Innovación. Agència d'Informació, Avaluació i Qualitat en Salut de Catalunya; 2011. Informes de Evaluación de Tecnologías Sanitarias, AIAQS núm. 2010/06.
52. Szypowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. *Eur J Endocrinol*. 2012 Apr;166(4):567-574.
53. Wei Q, Sun Z, Yang Y, Yu H, Ding H, Wang S. Effect of a CGMS and SMBG on maternal and neonatal outcomes in gestational diabetes mellitus: a randomized controlled trial. *Sci Rep*. 2016;6(87):1-9. doi:10.1038/srep19920.
54. Wentholt I, Hoekstra J, De Vries J. Continuous glucose monitors: the long-awaited watch dogs? *Diabetes Technol Ther*. 2007 Oct;9(5):399–409.
55. Wojciechowski P, Rys P, Lipowska A, Gaweska M, Malecki MT. Efficacy and safety comparison of continuous glucose monitoring and self-monitoring of blood

glucose in type 1 diabetes: systematic review and meta-analysis. *Pol Arch Med Wewn.* 2011;121(10):333-344.

56. Wong JC, Foster NC, Maahs DM, et al. Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. *Diabetes Care.* 2014;37(10):2702-2709. doi:10.2337/dc14-0303.
57. Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. *Ann Intern Med.* 2012 Sep 4;157(5):336-347.
58. Yoo HJ, An HG, Park SY, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. *Diabetes Res Clin Pract.* 2008 Oct;82(1):73-79.